https://www.benzinga.com/insights/short-sellers/24/12/42445232/halo-analyzing-halozyme-therapeuticss-short-interest
(HALO) - Analyzing Halozyme Therapeutics's Short Interest - Halozyme Therapeutics (NASDAQ:HALO) -...
halozyme therapeuticsshort interestanalyzingnasdaq
https://www.benzinga.com/quote/HALO/short-interest
Halozyme Therapeutics Stock Short Interest Report | NASDAQ:HALO | Benzinga
Short interest for Halozyme Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Halozyme Therapeutics's stock....
halozyme therapeuticsshort intereststockreportnasdaq
https://www.biospace.com/halozyme-therapeutics-inc-completes-enrollment-of-enhanze-technology-clinical-trial-to-improve-the-subcutaneous-absorption-of-a-large-protein-molecu
Halozyme Therapeutics, Inc. Completes Enrollment Of Enhanze Technology Clinical Trial To Improve...
halozyme therapeutics inc
https://www.benzinga.com/insights/analyst-ratings/25/01/42957472/analyst-expectations-for-halozyme-therapeuticss-future
Analyst Expectations For Halozyme Therapeutics's Future - Halozyme Therapeutics (NASDAQ:HALO) -...
analyst expectationshalozyme therapeuticsfuturenasdaq
https://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-upcoming-healthcare-conference-300604620.html
Halozyme Therapeutics To Present At Upcoming Healthcare Conference
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting...
halozyme therapeuticspresentupcominghealthcareconference
https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios
Halozyme Therapeutics, Inc. Common Stock (HALO) Price/Earnings & PEG Ratios | Nasdaq
Get updated information on Halozyme Therapeutics, Inc. Common Stock (HALO) Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluations with Nasdaq.
halozyme therapeutics inccommon stockprice earningspeg ratios
https://www.benzinga.com/insights/analyst-ratings/25/02/43460171/demystifying-halozyme-therapeutics-insights-from-8-analyst-reviews
Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews - Halozyme Therapeutics...
halozyme therapeuticsdemystifyinginsights8analyst
https://www.finanznachrichten.de/nachrichten-2026-04/68137978-halozyme-therapeutics-inc-halozyme-announces-global-collaboration-and-license-agreement-with-vertex-pharmaceuticals-for-hypercon-technology-008.htm
Halozyme Therapeutics, Inc.: Halozyme Announces Global Collaboration and License Agreement with...
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary,...
halozyme therapeutics incglobal collaborationlicense agreementannounces
https://www.marketscreener.com/quote/stock/HALOZYME-THERAPEUTICS-INC-50245/news/Halozyme-Therapeutics-Launches-Cash-Tender-Offer-to-Acquire-Antares-Pharma-Shares-40156458/
Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares | MarketScreener
Apr 26, 2022 - Halozyme Therapeutics said Tuesday it is launching a cash tender offer to acquire all outstanding common shares of Antares Pharma for $5.60 per share in cash....
halozyme therapeuticstender offer
https://www.nasdaq.com/market-activity/stocks/halo/short-interest
Halozyme Therapeutics, Inc. Common Stock (HALO) Short Interest | Nasdaq
Find the latest on short interest, settlement dates, average share volume, and days to cover for Halozyme Therapeutics, Inc. Common Stock (HALO) at Nasdaq.com.
halozyme therapeutics inccommon stockshort interestnasdaq
https://www.biospace.com/halozyme-therapeutics-inc-reports-first-quarter-2009-financial-results
Halozyme Therapeutics, Inc. Reports First Quarter 2009 Financial Results - BioSpace
halozyme therapeutics incfirst quarterfinancial resultsreports2009
https://theorg.com/org/halozyme-therapeutics/teams/sales-and-account-management
Halozyme Therapeutics - Sales and Account Management | The Org
The Sales and Account Management team at Halozyme Therapeutics is responsible for driving sales growth and managing relationships with healthcare providers and...
halozyme therapeuticsaccount managementsales
https://stockanalysis.com/stocks/halo/
Halozyme Therapeutics (HALO) Stock Price & Overview
A detailed overview of Halozyme Therapeutics, Inc. (HALO) stock, including real-time price, chart, key statistics, news, and more.
halozyme therapeuticsstock priceoverview
https://www.finanznachrichten.de/chart-tool/aktie/halozyme-therapeutics-inc.htm
HALOZYME THERAPEUTICS Chartanalyse
Chart zur HALOZYME THERAPEUTICS INC Aktie. Alle Charts zu Ihren Aktien.
halozyme therapeuticschartanalyse
https://www.fool.com/investing/2021/02/24/why-halozyme-therapeutics-is-trading-14-higher-tod/
Why Halozyme Therapeutics Is Trading 14% Higher Today | The Motley Fool
Feb 24, 2021 - Investors liked what they saw in the company's fourth-quarter earnings release.
halozyme therapeuticstrading
https://www.finanznachrichten.de/aktien-analysen/halozyme-therapeutics-inc.htm
HALOZYME THERAPEUTICS-AKTIE kaufen? Analysen, Kursziele & Empfehlungen zu A0DLHS
HALOZYME THERAPEUTICS-Aktie jetzt kaufen? Analysen und Kursziele:
halozyme therapeuticsaktie kaufenanalysenkurszieleempfehlungen
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-0j2o/halozyme-therapeutics-shares
Halozyme Therapeutics (LSE:0J2O) - Stock Analysis - Simply Wall St
Research Halozyme Therapeutics' (LSE:0J2O) fundamentals, past performance, valuation, dividends and more.
halozyme therapeuticsstock analysislsesimplywall
https://theorg.com/org/halozyme-therapeutics
Halozyme Therapeutics | The Org
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established...
halozyme therapeutics
https://theorg.com/org/halozyme-therapeutics?person=khushboo-soni
Halozyme Therapeutics | The Org
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established...
halozyme therapeutics
https://www.biospace.com/halozyme-therapeutics-inc-to-hold-third-quarter-2005-conference-call-on-november-11
Halozyme Therapeutics, Inc. To Hold Third Quarter 2005 Conference Call On November 11 - BioSpace
halozyme therapeutics inc
https://www.biospace.com/halozyme-therapeutics-inc-to-hold-2005-fourth-quarter-and-year-end-conference-call-on-march-23
Halozyme Therapeutics, Inc. To Hold 2005 Fourth Quarter And Year End Conference Call On March 23 -...
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/investors-in-halozyme-therapeutics-nasdaqhalo-have-seen-impr
Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past...
Halozyme Therapeutics, Inc. ( NASDAQ:HALO ) shareholders might be concerned after seeing the share price drop 17% in...
https://www.biospace.com/halozyme-therapeutics-inc-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-conference
Halozyme Therapeutics, Inc. To Present At The Bank of America Merrill Lynch 2015 Health Care...
bank of america merrill lynch
https://www.biospace.com/horizon-therapeutics-plc-and-halozyme-therapeutics-inc-enter-global-collaboration-and-license-agreement-for-enhanze-technology
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License...
Nov 23, 2020 - Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives...
horizon therapeuticshalozyme incglobal collaborationplcenter